ABVD Versus A+AVD as Front-Line Treatment in Hodgkin Lymphoma

July 3, 2014
Anas Younes, MD

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses a phase III trial of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses a phase III trial of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma.

Clinical Pearls:

  • The current standard of care for patients with classical Hodgkin lymphoma in the front-line setting is ABVD.
  • The phase I trial showed promising results in terms of safety and efficacy.
  • This randomized, multicenter, phase III trial comparing ABVD with A+AVD has the potential to change the standard of care.